Maxime Dely: Therapeutic Apheresis – How Do You Know When You Can’t Wait Any Longer?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Therapeutic Apheresis: How do you know when you can’t wait any longer?
3 clinical criteria to decide on Therapeutic Apheresis
Therapeutic apheresis is neither an automatic reflex nor a last-resort treatment by default. The right indication relies on a structured clinical reasoning, which can be summarized into three key criteria.
1. A clearly identifiable circulating pathogenic target
Apheresis makes sense when the disease mechanism involves a blood-borne factor that can be mechanically removed:
– autoantibodies (TTP, myasthenia gravis, Goodpasture syndrome)
– immune complexes (severe lupus)
– abnormal cells (leukostasis in acute leukemias)
– lipoproteins (homozygous familial hypercholesterolemia)
Without a clearly identified circulating target, the expected benefit becomes questionable.
2. Acute or rapidly progressive clinical severity
Myasthenic crisis with respiratory failure, thrombotic thrombocytopenic purpura, progressive Guillain–Barré syndrome, antibody-mediated graft rejection…
In these situations, apheresis is a life-saving or organ-saving emergency intervention.
3. A mismatch between clinical urgency and the onset of action of standard therapies
Immunosuppressive drugs, IVIg, or chemotherapy may be effective — but sometimes too slow.
Therapeutic apheresis allows an immediate reduction of the pathogenic burden, stabilizing the patient and creating a therapeutic window.
Deciding on apheresis is not about ticking boxes on a list of indications. It is about integrating pathophysiology, clinical severity, and timing, through close multidisciplinary collaboration.
When properly indicated, apheresis is not a technical luxury — it is a strategic clinical tool.”

Find more posts featuring Maxime Dely on Hemostasis Today.
-
Aug 22, 2026, 11:36Bernardo Gindri: How platelets Influence Cancer Progression
-
Aug 22, 2026, 11:34Nick Gehrig: Extending Platelet Shelf Life to Strengthen Blood Supply
-
Aug 22, 2026, 11:14Lei Yu: New Guidance for Acute Pulmonary Embolism in 2026
-
Aug 22, 2026, 11:01Neeraj Songara: Shelf-Stable Synthetic Blood – The Future of Emergency Transfusion?
-
Aug 22, 2026, 10:41Mike R.։ VTE Thrombectomy – Defining What Success Really Means
-
Aug 22, 2026, 10:28Steven Meier: What Happens During PRP Therapy?
-
Aug 22, 2026, 10:05Ralf Ludwig: When a Promising Biomarker Falls Short
-
Aug 22, 2026, 09:33Mary Cushman: What Causes PE to Happen in People with DVT?
-
Aug 22, 2026, 07:45Ziad Hijazi: Refining Risk Assessment in Atrial Fibrillation Without Oral Anticoagulation